GeneDx stockholders can seek lead plaintiff role in class action over alleged misleading acquisition disclosures.

GeneDx Holdings Corp. faces a class action lawsuit alleging it misled investors about the viability of Fabric Genomics, a company it acquired. The lawsuit claims GeneDx and executives made false statements and failed to disclose problems that hurt business, leading to a 49% stock drop after poor Q1 2026 results were announced. Investors who bought GeneDx stock between April 16, 2025, and May 4, 2026, can apply to be lead plaintiff by August 3, 2026. The lead plaintiff will represent all class members in the case, potentially influencing the litigation's direction and recovery efforts.